Market Research Logo

Down Syndrome - Pipeline Review, H2 2015

Down Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Down Syndrome - Pipeline Review, H2 2015’, provides an overview of the Down Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Down Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Down Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Down Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Down Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Down Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Down Syndrome Overview
Therapeutics Development
Pipeline Products for Down Syndrome - Overview
Pipeline Products for Down Syndrome - Comparative Analysis
Down Syndrome - Therapeutics under Development by Companies
Down Syndrome - Therapeutics under Investigation by Universities/Institutes
Down Syndrome - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Down Syndrome - Products under Development by Companies
Down Syndrome - Products under Investigation by Universities/Institutes
Down Syndrome - Companies Involved in Therapeutics Development
AC Immune SA
Aelis Farma S.A.S.
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
NeuroNascent, Inc.
Transition Therapeutics Inc.
Down Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACI-24 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APH-1104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BTD-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-217 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
donepezil hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ELND-005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NNI-351 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-1662 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule DYRK1A Inhibitor for CNS Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Down Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Down Syndrome - Recent Pipeline Updates
Down Syndrome - Discontinued Products
Down Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics
Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome
Apr 07, 2014: Transition Therapeutics Announces Development Update
Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome
Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome
Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Down Syndrome, H2 2015
Number of Products under Development for Down Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Down Syndrome - Pipeline by AC Immune SA, H2 2015
Down Syndrome - Pipeline by Aelis Farma S.A.S., H2 2015
Down Syndrome - Pipeline by Eisai Co., Ltd., H2 2015
Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Down Syndrome - Pipeline by NeuroNascent, Inc., H2 2015
Down Syndrome - Pipeline by Transition Therapeutics Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Down Syndrome Therapeutics - Recent Pipeline Updates, H2 2015
Down Syndrome - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Down Syndrome, H2 2015
Number of Products under Development for Down Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report